RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Bladerunner, One could just as easily ask why Organon would put a different AMPA upmodulator into the clinic if they're so happy with Org-24448? So the logic can go both ways. BTW, I don't think it's been firmly established yet that Org-26576 is definitely a Cortex developed compound. It probably is, but Organon does have some AMPA upmodulators of their own. As we saw, Servier decided to go ahead with their own non-Cortex compound, so it's possible that Organon might have also. Also, it's not impossible that the cellular problem is only a class wide phenomenon within Cortex's benzamide family.

All I'm saying is that based on the numerous landmines we've hit over the past year, we should be careful with our assumptions, particularly the rosy type. The only thing we know for sure is that Murphy's Law is still alive and well.

One thing that worries me is that if they're doing their job right, the FDA SHOULD want to see additional tox data on Org-24448. That would only be logical and prudent, since Org-24448 is the sister compound of CX-717. In a presentation a while back, Dr. Stoll explained how Org-24448 was tweaked structurally to create CX-717, to improve upon some of the less favorable metabolic issues seen with Org-24448. If the FDA is being as cautious as they appear to be, there's a reasonable chance that they'll want to see additional data on Org-24448. That possibility is something we need to consider in our risk analysis of this stock.